

Special Issue

Antibody Response to Infection and Vaccination

Message from the Guest Editors

This Special Issue aims to cover experimental results, clinical studies, methods, and technology that facilitate understanding of antibody response to infection and vaccination. We are pleased to invite you to submit your studies. This Special Issue will publish original research, reviews, perspectives, and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research. Research areas may include (but not be limited to) the following: antibody responses elicited by infection and by different vaccines, antibody neutralization mechanism, antibody-mediated immune pathogenicity, T-B cell interactions, antibody clonal evolution, mucosal antibody responses, broadly neutralizing antibody response, antibody immune escape by pathogens, and technologies and methods for understanding antibody responses. The emphasis is on viruses, but other pathogens, such as bacteria, fungi, and parasites, are also welcomed. We hope this Special Issue serves as a platform for researchers to exchange the latest progress in antibody response to infections and vaccinations. We look forward to receiving your contributions.

Guest Editors

Dr. Zhiqiang Ku

Institute of Molecular Medicine McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Dr. Xiaohua Ye

Institute of Molecular Medicine McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/102346

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).